[144] Protagonist Therapeutics, Inc SEC Filing

Rhea-AI Filing Summary

PTGX has a planned sale of 108,273 common shares under Rule 144, with an aggregate market value of $9,162,061. The shares are to be sold through J.P. Morgan Securities LLC on the Nasdaq, with an approximate sale date of 01/23/2026, and the filing notes 62,515,666 shares of this class outstanding.

The person for whose account the securities will be sold acquired these shares directly from the issuer on 01/23/2026 via cash option exercises in two transactions of 30,000 and 78,273 shares. The signer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Commom	J.P. Morgan Securities LLC 270 Park Avenue 10th Floor New York NY 10017	108273	9162061	62515666	01/23/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/23/2026	Option Exercise	Issuer			30000	01/23/2026	Cash
Common	01/23/2026	Option Exercise	Issuer			78273	01/23/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does PTGX's Form 144 filing disclose?

The filing discloses that a holder plans to sell 108,273 shares of PTGX common stock under Rule 144, with an aggregate market value of $9,162,061, through J.P. Morgan Securities LLC on the Nasdaq.

How many PTGX shares are planned to be sold and what is their value?

The notice covers a planned sale of 108,273 common shares of PTGX with an aggregate market value of $9,162,061, as stated in the filing.

How were the PTGX shares in this Form 144 acquired?

The shares were acquired from the issuer on 01/23/2026 through cash option exercises in two transactions of 30,000 and 78,273 common shares.

Which broker and exchange are involved in the planned PTGX share sale?

The planned sale will be executed through J.P. Morgan Securities LLC, and the shares are listed for trading on the Nasdaq.

How many PTGX shares of this class are outstanding according to the filing?

The filing states that there are 62,515,666 PTGX common shares outstanding for this class of securities.

What representation does the seller make about PTGX's information in the Form 144?

The person for whose account the securities will be sold represents that they do not know any material adverse information about PTGX’s current or prospective operations that has not been publicly disclosed.